[1] Boussiotis VA.Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med,2016,375(18):1767-1778.
[2] Chen L, Han X.Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future[J]. J Clin Invest,2015, 125(9):3384-3391.
[3] Tang J, Shalabi A, Hubbard-Lucey VM.Comprehensive analysis of the clinical immuno-oncology landscape[J]. Ann Oncol,2018,29(1):84-91.
[4] Tan PS, Aguiar P Jr, Haaland B, et al.Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systema-tic review and network meta-analysis of 3024 participants[J]. Lung Cancer,2018,115:84-88.
[5] Carbognin L, Pilotto S, Milella M, et al.Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1(PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers[J]. PLoS One,2015,10(6):e0130142.
[6] Weber JS, D′angelo SP, Minor D, et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol,2015,16(4):375-384.
[7] Robert C, Long GV, Brady B, et al.Nivolumab in previou-sly untreated melanoma without BRAF mutation[J]. N Engl J Med,2015,372(4):320-330.
[8] Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.Over-all survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med,2017,377(14):1345-1356.
[9] Ribas A, Puzanov I, Dummer R, et al.Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial[J]. Lancet Oncol,2015,16(8):908-918.
[10] Schachter J, Ribas A, Long GV, et al.Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study(KEYNOTE-006)[J]. Lancet,2017,390(10105):1853-1862.
[11] Robert C, Schachter J, Long GV, et al.Pembrolizumab versus Ipilimumab in Advanced Melanoma[J]. N Engl J Med,2015,372(26):2521-2532.
[12] Sharma P, Retz M, Siefker-Radtke A, et al.Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol,2017,18(3):312-322.
[13] Bellmunt J, De Wit R, Vaughn DJ, et al.Pembrolizumab as second-line therapy for advanced urothelial carcinoma[J]. N Engl J Med,2017,376(11):1015-1026.
[14] Rosenberg JE, Hoffman-Censits J, Powles T, et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet,2016,387(10031):1909-1920.
[15] Powles T, O′donnell PH, Massard C, et al.Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-iabel study[J]. JAMA Oncol,2017,3(9):e172411.
[16] Balar AV, Galsky MD, Rosenberg JE, et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. Lancet,2017,389(10064):67-76.
[17] Brahmer J, Reckamp KL, Baas P, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med,2015,373(2):123-135.
[18] Herbst RS, Baas P, Kim DW, et al.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010): a randomised controlled trial[J]. Lancet,2016,387(10027):1540-1550.
[19] Reck M, Rodriguez-Abreu D, Robinson AG, et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med,2016,375(19):1823-1833.
[20] Langer CJ, Gadgeel S, Borghaei H, et al.Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol,2016,17(11):1497-1508.
[21] Rittmeyer A, Barlesi F, Waterkamp D, et al.Atezolizu-mab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet,2017, 389(10066):255-265.
[22] Fehrenbacher L, Spira A, Ballinger M, et al.Atezolizu-mab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet,2016,387(10030):1837-1846.
[23] El-Khoueiry AB, Sangro B, Yau T, et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet,2017,389(10088):2492-2502.
[24] Chen SC, Chao Y, Yang MH.Complete response to the combination of pembrolizumab and sorafenib for metastatic hepatocellular carcinoma: A case report[J]. Am J Gastroenterol,2017,112(4):659-660.
[25] Overman MJ, Mcdermott R, Leach JL, et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol,2017,18(9):1182-1191.
[26] Ferris RL, Blumenschein G Jr, Fayette J, et al.Nivolu-mab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2016,375(19):1856-1867.
[27] Motzer RJ, Escudier B, Mcdermott DF, et al.Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med,2015,373(19):1803-1813.
[28] Younes A, Santoro A, Shipp M, et al.Nivolumab for classical Hodgkin's lymphoma after failure of both auto-logous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial[J]. Lancet Oncol,2016,17(9):1283-1294.
[29] Chen R, Zinzani PL, Fanale MA, et al.PhaseⅡ study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma[J]. J Clin Oncol,2017, 35(19):2125-2132.
[30] Ansell SM, Lesokhin AM, Borrello I, et al.PD-1 bloc-kade with nivolumab in relapsed or refractory Hodgkin′s lymphoma[J]. N Engl J Med,2015,372(4):311-319.
[31] Kaufman HL, Russell J, Hamid O, et al.Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial[J]. Lancet Oncol,2016,17(10):1374-1385.
[32] Taylor M, Dutcus CE, Schmidt E, et al.A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors[J]. Ann Oncol,2016,27(suppl 6):266-295.
[33] Makker V, Rasco DW, Dutcus CE, et al.A phase Ⅰb/Ⅱ trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma[J]. J Clin Oncol,2017,35(suppl_15):5598-5598.
[34] Lee CH, Makker V, Rasco D, et al.A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma[J]. Ann Oncol,2017,28(suppl_5):295-296.
[35] Postow MA, Callahan MK, Wolchok JD.Immune checkpoint blockade in cancer therapy[J]. J Clin Oncol,2015, 33(17):1974-1982.
[36] Friedman CF, Proverbs-Singh TA, Postow MA.Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncol,2016,2(10):1346-1353.
[37] Calabrese L, Mariette X.The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy[J]. Ann Rheum Dis,2018,77(2):162-164.
[38] Hawkes EA, Grigg A, Chong G.Programmed cell death-1 inhibition in lymphoma[J]. Lancet Oncol,2015,16(5):e234-e245.
[39] Weber JS, Postow M, Lao CD, et al.Management of adverse events following treatment with anti-programmed death-1 agents[J]. Oncologist,2016,21(10):1230-1240.
[40] Freeman-Keller M, Kim Y, Cronin H, et al.Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes[J]. Clin Cancer Res,2016,22(4):886-894.
[41] Routy B, Le Chatelier E, Derosa L, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science,2017,359(6371):91-97.
[42] Gopalakrishnan V, Spencer CN, Nezi L, et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science,2017,359(6371):97-103.
[43] Nishino M, Ramaiya NH, Hatabu H, et al.Monitoring immune-checkpoint blockade: response evaluation and biomarker development[J]. Nat Rev Clin Oncol,2017, 14(11):655-668.
[44] Remon J, Chaput N, Planchard D.Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer[J]. Curr Opin Oncol,2016,28(2):122-129.
[45] Lau E.Mismatch repair deficiency predicts benefit of anti-PD-1 therapy[J]. Lancet Oncol,2015,16(7):e319.
[46] Le DT, Durham JN, Smith KN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science,2017,357(6349):409-413.
[47] Le DT, Uram JN, Wang H, et al.PD-1 Blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med,2015,372(26):2509-2520.
[48] Huang AC, Postow MA, Orlowski RJ, et al.T-cell invigoration to tumour burden ratio associated with anti-PD-1 response[J]. Nature,2017,545(7652):60-65. |
